Jump to section
Aignostics' mission is to help take drug research from visual estimations under a microscope to precise analysis and quantification
Some candidates hear
back within 2 weeks
47% employee growth in 12 months
Manual microscopes are an incredible advancement in medical history. They provide an evaluation of tissue samples that enable the diagnosis of cancer as well as multiple degenerative, infectious and inflammatory diseases. With this said, there has been a worldwide increase in the numbers and complexity of cancer cases, as well as a predicted global shortage of pathologists. Manual analysis does not have the precision and capability to provide deeper conclusions from data to support the precision medicine and drug development processes of the future.
Aignostics recognise this issue. They are an interdisciplinary team of machine learners, data scientists, pathologists, software engineers and business professionals dedicated to taking explainable AI from their research lab into the wider world.
Aignostics plan to expand its portfolio in pharmaceutical research and fund longer-term projects that are aimed at developing companion/complementary diagnostics (CDx) applications for clinical routine. It will also increase its focus on the US market, leveraging its already considerable presence in Europe to make the jump across the Atlantic.
Steph
Company Specialist at Welcome to the Jungle
Oct 2024
$34m
SERIES B
Sep 2022
$14.8m
SERIES A
Viktor Matyas
(CEO)Viktor has experience as a Research Analyst at Arthur D Little, and Junior Engagement Manager at McKinsey.
Maximilian Alber
(CTO)Previously Intern at Google and Researcher at Berlin Institute of Technology.
Software Engineering
Data
Finance, Legal & Compliance